Medline
Medline's revenue rose 11.5% to $28.4 billion in fiscal 2025. Its operating margin was 7.8%, down from 8.4% a year earlier. Free cash flow was $1.3 billion, down 8.3%. It paid out $33 million in dividends and buybacks, 3% of free cash flow.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Income statement
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | 1.6 | 0.2 | 1.9 |
| Debt incl. finance leases | — | 16.5 | 12.6 |
| Net debt (negative means net cash) | — | 16.3 | 10.6 |
| Net debt to EBITDA | — | 5.2x | 3.3x |
| Debt to equity | — | — | 1.2x |
| Interest coverage | 1.0x | 1.9x | 2.3x |
| Current ratio | — | 3.4x | 4.3x |
| Quick ratio | — | 1.6x | 2.4x |
Cash flow
Projections
Project Medline's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Medline says to expect
- Full year 2026: organic sales growth and Adjusted EBITDA
The Company is raising its full year 2026 outlook for Organic Sales 2 growth to 10.0% to 10.5%, compared to its previous outlook of 9.0% to 10.0%, and reaffirming its Adjusted EBITDA 2 outlook of $3.3 billion to $3.4 billion.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 4 insiders bought $515.0 million of Medline shares on the open market, and 11 insiders sold $7.2 billion, $3.7 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | Hux Investment Pte. Ltd.10% owner | Sold | 100,000 | $35.80 | $3.6 million | Form 4 |
| Aug 13, 2026 | Hux Investment Pte. Ltd.10% owner | Sold | 1,500,000 | $35.80 | $53.7 million | Form 4 |
| Aug 7, 2026 | GIC Private Ltd10% owner | Sold | 590,284 | $35.58 | $21.0 million | Form 4 |
| Aug 6, 2026 | Hux Investment Pte. Ltd.10% owner | Sold | 271,994 | $35.33 | $9.6 million | Form 4 |
| Aug 5, 2026 | Hux Investment Pte. Ltd.10% owner | Sold | 1,976,618 | $35.60 | $70.4 million | Form 4 |
| Jun 16, 2026 | Douglas P GolwasChief Commercial Officer, 10% owner | Sold plan | 100,000 | $36.77 | $3.7 million | Form 4 |
| Jun 5, 2026 | Jessi L CorcoranPrincipal Accounting Officer | Bought | 5,000 | $34.15 | $170,750 | Form 4 |
| May 28, 2026 | BX Mozart ML-2 Holdco GP L.L.C.10% owner | Sold | 33,317,824 | $36.54 | $1.2 billion | Form 4 |
| May 28, 2026 | Mend Partners II L.P.10% owner | Sold | 31,868,237 | $36.54 | $1.2 billion | Form 4 |
| Mar 10, 2026 | Mozart Aggregator II UNLV Holdco L.P.10% owner | Sold | 27,852,986 | $40.51 | $1.1 billion | Form 4 |
| Mar 10, 2026 | TC Group Cayman Investment Holdings Sub L.P.10% owner | Sold | 26,105,840 | $41.00 | $1.1 billion | Form 4 |
| Mar 10, 2026 | HFCP X (Parallel-A) L.P.10% owner | Sold | 26,131,237 | $40.51 | $1.1 billion | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 |
|---|---|---|
| Piotroski F-score | — | — |
| Rule of 40 | 15.3% | 16.0% |
| Altman Z'' | — | 2.84 |
| Accruals ratio | — | −1.6% |
The nine F-score tests
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | — | Pass |
| Cash from operations is positive | Pass | Pass |
| Return on assets rose | — | — |
| Cash from operations exceeds net income | Pass | Pass |
| Debt fell relative to assets | — | — |
| Current ratio rose | — | Pass |
| Share count didn't rise | — | — |
| Gross margin rose | Pass | Fail |
| Revenue rose relative to assets | — | — |
| F-score | — | — |
Compare
Put Medline side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Medline | FY25 | 11.5% | 7.8% | 4.6% | — | 3.3x | — | |
| Henry Schein | FY25 | 4.0% | 5.0% | 4.3% | 7.5% | 3.1x | 6 | Compare |
| 111 | FY25 | −12.8% | −0.0% | 0.9% | — | — | — | Compare |
| Cardinal Health | FY26 | 14.2% | 1.0% | 1.8% | — | 1.1x | 6 | Compare |
| Accendra Health | FY25 | 3.1% | 1.0% | −10.6% | 1.2% | 7.3x | 2 | Compare |
3 years of figures
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | 23.2 | 25.5 | 28.4 |
| Revenue growth | — | 9.8% | 11.5% |
| Gross profit | 5.9 | 7.0 | 7.5 |
| Research and development | 0.1 | 0.1 | 0.1 |
| Operating income | 1.2 | 2.1 | 2.2 |
| Net income | 0.2 | 1.2 | 1.2 |
| Diluted EPS (US$) | — | — | −0.01 |
| Diluted shares (millions) | — | — | 810 |
| Cash flow | |||
| Cash from operations | 1.7 | 1.8 | 1.7 |
| Capital expenditure | 0.3 | 0.4 | 0.4 |
| Free cash flow | 1.4 | 1.4 | 1.3 |
| Dividends paid | 0.0 | 0.0 | 0.0 |
| Share buybacks | 0.0 | 0.0 | 0.0 |
| Acquisitions | 0.0 | 1.1 | 0.0 |
| Stock-based compensation | 0.1 | 0.1 | 0.1 |
| Balance sheet at fiscal year end | |||
| Cash and short-term investments | 1.6 | 0.2 | 1.9 |
| Debt incl. finance leases | — | 16.5 | 12.6 |
| Total assets | — | 36.0 | 38.5 |
| Total liabilities | — | 19.5 | 19.2 |
| Shareholders' equity | — | — | 10.7 |
| Margins and ratios | |||
| Gross margin | 25.3% | 27.4% | 26.4% |
| Operating margin | 5.4% | 8.4% | 7.8% |
| Net margin | 1.0% | 4.6% | 4.1% |
| Free cash flow margin | 6.1% | 5.5% | 4.6% |
| Rule of 40 (growth + FCF margin) | — | 15.3% | 16.0% |
| Return on capital | — | — | — |
| Return on equity | — | — | — |
| Return on assets | — | — | 3.1% |
| Net debt to EBITDA | — | 5.2x | 3.3x |